Eyetelligence is a MedTech company, innovating to set the new benchmark in accurate and efficient patient care. We empower people with advanced AI and automation, using the eye as the gateway to detect and prevent diseases in the earliest stages.
Our flagship product, Eyetelligence Assure, is already supporting optometrists in the screening and management of three major eye diseases that cause preventable blindness. This same technology is also able to detect signs of up to 139 additional eye diseases.
As we continue to work towards our goal, we are now finalising an AI model that can assess microvascular health of the eye, using it as an accurate risk assessment tool for the vascular health of a patient, all from a digital fundus image.
Eyetelligence is the result of a decade of intensive research, based on the initial AI tool known as Eyegrader, developed by Professor Mingguang He and his colleagues in China.
Professor He joined CERA (Centre for Eye Research Australia) in 2015, and Eyetelligence Pty Ltd was established in Australia in 2019, to further develop and commercialise the AI decision support software.